Boston Children's Hospital is monitoring the developing situation with lead contamination in some Boston Public Schools. Please contact your primary care physician if you have any concerns about your child.
Boston Children’s Hospital está monitoreando la situación de la contaminación por plomo en algunas escuelas públicas de Boston. Por favor, póngase en contacto con su médico primario si usted tiene alguna preocupación acerca de su hijo.
Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Solid tumors represent a wide variety of pediatric cancers. Some of the more prevalent forms of these cancers are neuroblastoma, osteosarcoma, Ewing sarcoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, and liver and germ cell tumors. Patients generally require a combination of treatments that may include surgical removal of the tumor, chemotherapy and radiation therapy.
Children with solid tumors are treated through the Solid Tumor Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children's Hospital. Our doctors provide unparalleled expertise in the diagnosis, treatment and management of these diseases. Dana-Farber/Boston Children’s was one of the first centers in the United States to use adjuvant chemotherapy and perform limb salvage surgery for patients with osteosarcoma. The team continues to advance the treatment of pediatric solid tumors by offering unique therapies, such as radioiodine-labeled metaiodobenzylguanidine (I-131 MIBG) treatment for neuroblastoma.
Our multidisciplinary approach to care ensures in-depth discussion of each case and personalized treatment plans for every patient. We integrate expertise from the following specialists:
Learn more about the the Solid Tumor Center Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”